NASDAQ:ARGX argenex (ARGX) Stock Price, News & Analysis $972.25 +12.76 (+1.33%) Closing price 04:00 PM EasternExtended Trading$972.77 +0.52 (+0.05%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About argenex Stock (NASDAQ:ARGX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get argenex alerts:Sign Up Key Stats Today's Range$954.76▼$977.0150-Day Range$830.79▼$1,058.9052-Week Range$661.85▼$1,072.75Volume264,657 shsAverage Volume229,033 shsMarket Capitalization$60.82 billionP/E Ratio37.34Dividend YieldN/APrice Target$1,158.61Consensus RatingModerate Buy Company Overview argenx SE (NASDAQ:ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company combines antibody engineering technologies with disease biology to discover medicines that target the underlying mechanisms of immune-mediated disorders. argenx’s leading product is efgartigimod, marketed as Vyvgart and Vyvgart Hytrulo in the United States. The therapies are designed to reduce disease-causing immunoglobulin G (IgG) antibodies by targeting the neonatal Fc receptor (FcRn). They are used in certain patients with generalized myasthenia gravis, and efgartigimod has also received regulatory approvals for chronic inflammatory demyelinating polyneuropathy and other indications in selected markets. Founded in 2008, argenx is headquartered in Ghent, Belgium, with operations and commercial activities in the United States and other international markets. The company continues to develop efgartigimod for additional autoimmune conditions and maintains a broader pipeline of investigational therapies. Tim Van Hauwermeiren serves as chief executive officer.AI Generated. May Contain Errors. Read More argenex Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreARGX MarketRank™: argenex scored higher than 86% of companies evaluated by MarketBeat, and ranked 49th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus Ratingargenex has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 2 strong buy ratings, 17 buy ratings, 5 hold ratings, and no sell ratings.Upside Potentialargenex has a consensus price target of $1,158.61, representing about 19.2% upside from its current price of $972.25.Amount of Analyst Coverageargenex has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about argenex's stock forecast and price target. Earnings and Valuation3.8 / 5Proj. Earnings Growth27.94% Earnings GrowthEarnings for argenex are expected to grow by 27.94% in the coming year, from $29.13 to $37.27 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of argenex is 37.34, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.53.Price to Earnings Ratio vs. SectorThe P/E ratio of argenex is 37.34, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.76.Price to Earnings Growth Ratioargenex has a PEG Ratio of 0.99. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share Ratioargenex has a P/B Ratio of 8.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted2.15% of the float of argenex has been sold short.Short Interest Ratio / Days to Coverargenex has a short interest ratio ("days to cover") of 6.31.Change versus previous monthShort interest in argenex has recently increased by 4.27%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend Yieldargenex does not currently pay a dividend.Dividend Growthargenex does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.49 News Sentimentargenex has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for argenex this week, compared to 8 articles on an average week.Search InterestOnly 15 people have searched for ARGX on MarketBeat in the last 30 days. This is a decrease of -29% compared to the previous 30 days.MarketBeat Follows7 people have added argenex to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, argenex insiders have not sold or bought any company stock.Percentage Held by Insiders2.43% of the stock of argenex is held by insiders.Percentage Held by Institutions60.32% of the stock of argenex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about argenex's insider trading history. Receive ARGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for argenex and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARGX Stock News HeadlinesHere's Exactly Why Wall Street Thinks Argenx Stock Could Soar 23% Over the Next 12 MonthsSeptember 26 at 4:44 AM | fool.comargenx (ENXTBR:ARGX) Shares Moved, So What Is Drawing Attention Now?September 24, 2026 | finance.yahoo.comAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly 80% afterward. He also called the housing crisis and the collapse of Bear Stearns and Lehman Brothers before they happened. Now Tilson says the day after this year's midterm elections, America enters a period of economic change unlike anything seen in decades - and most investors are unprepared.September 28 at 1:00 AM | Stansberry Research (Ad)argenx (ENXTBR:ARGX) Stock Could Be Pricey Despite Strong Earnings ExpectationsSeptember 23, 2026 | finance.yahoo.comStock market today: Small caps, gold miners spanked amid selloff; Meta makes a bullish moveSeptember 23, 2026 | msn.com2 Wall Street Analysts Think Argenx Can Soar More Than 40%. Here's Why They're Right.September 20, 2026 | fool.comargenex (NASDAQ:ARGX) Cut to "Hold" at Wall Street ZenSeptember 19, 2026 | americanbankingnews.comargenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive DirectorsSeptember 17, 2026 | globenewswire.comSee More Headlines ARGX Stock Analysis - Frequently Asked Questions How have ARGX shares performed this year? argenex's stock was trading at $840.95 at the beginning of the year. Since then, ARGX shares have increased by 15.6% and is now trading at $972.25. How were argenex's earnings last quarter? argenex SE (NASDAQ:ARGX) released its quarterly earnings results on Tuesday, July, 21st. The company reported $7.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.86 by $1.46. The business earned $1.54 billion during the quarter, compared to analyst estimates of $1.45 billion. argenex had a trailing twelve-month return on equity of 43.59% and a net margin of 32.19%. Read the conference call transcript. When did argenex IPO? argenex (ARGX) raised $97 million in an IPO on Thursday, May 18th 2017. The company issued 5,865,000 shares at a price of $16.62 per share. Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are argenex's major shareholders? Top institutional shareholders of argenex include Wellington Management Group LLP (1.49%), Squarepoint Ops LLC (0.09%), Handelsbanken Fonder AB (0.08%) and Peregrine Capital Management LLC (0.05%). How do I buy shares of argenex? Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of argenex own? Based on aggregate information from My MarketBeat watchlists, some other companies that argenex investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Broadcom (AVGO), Taiwan Semiconductor Manufacturing (TSM), CrowdStrike (CRWD) and Adobe (ADBE). Company Calendar Last Earnings7/21/2026Today9/28/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ARGX's financial health is in the Green zone, according to TradeSmith. ARGX has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ARGX Previous SymbolNASDAQ:ARGX CIK1697862 Webwww.argenx.com Phone(176) 303-0488FaxN/AEmployees1,863Year Founded2008Price Target and Rating Average Price Target for argenex$1,158.61 High Price Target$1,415.00 Low Price Target$910.00 Potential Upside/Downside+19.2%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage24 Analysts Profitability EPS (Trailing Twelve Months)$26.04 Trailing P/E Ratio37.34 Forward P/E Ratio33.38 P/E Growth0.99Net Income$1.29 billion Net Margins32.19% Pretax Margin32.80% Return on Equity43.59% Return on Assets36.66% Debt Debt-to-Equity RatioN/A Current Ratio5.12 Quick Ratio4.89 Sales & Book Value Annual Sales$4.25 billion Price / Sales14.32 Cash Flow$21.62 per share Price / Cash Flow44.98 Book Value$118.34 per share Price / Book8.22Miscellaneous Outstanding Shares62,560,000Free Float61,041,000Market Cap$60.82 billion OptionableOptionable Beta0.47 Social Links 10 Best Stocks to Own: Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:ARGX) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding argenex SE Please log in to your account or sign up in order to add this asset to your watchlist. Share argenex With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
